Clinical Trials Logo

Hepatic Carcinoma clinical trials

View clinical trials related to Hepatic Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06182865 Not yet recruiting - Hepatic Carcinoma Clinical Trials

A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in patients with hepatocellular carcinoma before and after proton therapy.

NCT ID: NCT03149523 Not yet recruiting - Clinical trials for Colorectal Adenocarcinoma

Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors

ExhauCRF
Start date: May 2017
Phase: N/A
Study type: Observational

Over the last 10 years, technological advances in molecular biology enabled a more accurate genomic characterization of tumors. For each tumor location, this led to the identification of subgroups with similar molecular characteristics. This identification allowed the development of targeted therapies and thus to improve the patient prognosis. This molecular characterization has also revealed the tumor heterogeneity. It may be the cause of treatment resistance and therefore of relapses. Additionally, tumor cells are in constant dialogue with their microenvironment composed of different immune or non immune cells. This microenvironment is now targeted in cancer treatment. To date, there are few studies that combine a deep genomic characterization of both tumor and tumor microenvironment of the patient. Combining the two types of studies on the same tumor should help to define new therapeutic targets and should allow a combination of targeted and immunomodulatory therapies. To this end, our project is to conduct an exhaustive integrated exploratory analysis at genomic, transcriptomic and immunological levels of 3 tumor types (in colon, kidney and liver cancer).